结直肠癌风险在线预测计算器的临床应用进展
|
摘要
目的了解结直肠癌风险在线预测计算器(CRC-PRO)在结直肠癌筛查中的应用现状,以分析其在我国可能具有的实用价值。方法检索国内外有关CRC-PRO的研究文献,对此工具的概况和应用现状作一综述。结果 CRC-PRO能预测个体发展成为结直肠癌的10年风险概率,可以快速为临床医生提供准确的患者风险估计,以帮助临床医生和患者确定筛查方案,从而改善预防策略。结论 CRC-PRO不仅能具体给出风险概率值,而且简单易操作,但是基于地域的差异,在CRC-PRO的推广中,需要开展多中心研究,以在更多不同的人群中进行更广泛的临床分析验证,进一步扩展此工具的应用范围。
Objective To understand the status of application of Colorectal Cancer Predicted Risk Online(CRCPRO) in colorectal cancer screening, and to analyze the possible practical value in our country. Methods The research literatures on the colorectal cancer risk prediction tool of CRC-PRO at home and abroad were searched. The overview and application status of this tool were reviewed. Results CRC-PRO could predict the 10-year risk rate of individuals developing colorectal cancer. It could quickly provide clinicians with accurate estimates of patient risk to help clinicians and patients identify screening programs and improve prevention strategies. Conclusions CRC-PRO can not only give specific probability of risk, but also easy to operate. But based on regional differences, in the promotion of CRC-PRO, it is necessary to carry out multi-center research in more diverse populations for more extensive clinical analysis and verification, to further expand the scope of application of this tool.
Objective To understand the status of application of Colorectal Cancer Predicted Risk Online(CRCPRO) in colorectal cancer screening, and to analyze the possible practical value in our country. Methods The research literatures on the colorectal cancer risk prediction tool of CRC-PRO at home and abroad were searched. The overview and application status of this tool were reviewed. Results CRC-PRO could predict the 10-year risk rate of individuals developing colorectal cancer. It could quickly provide clinicians with accurate estimates of patient risk to help clinicians and patients identify screening programs and improve prevention strategies. Conclusions CRC-PRO can not only give specific probability of risk, but also easy to operate. But based on regional differences, in the promotion of CRC-PRO, it is necessary to carry out multi-center research in more diverse populations for more extensive clinical analysis and verification, to further expand the scope of application of this tool.
引文
1Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2017:a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin, 2017, 67(2):100-121.
2Navarro M, Nicolas A, Ferrandez A, et al. Colorectal cancer population screening programs worldwide in 2016:an update.World J Gastroenterol, 2017, 23(20):3632-3642.
3Day LW, Velayos F. Colorectal cancer screening and surveillance in the elderly:updates and controversies. Gut Liver, 2015, 9(2):143-151.
4Freedman AN, Slattery ML, Ballard-Barbash R, et al. Colorectal cancer risk prediction tool for white men and women without known susceptibility. J Clin Oncol, 2009, 27(5):686-693.
5丁兰君,赵丽中,王媛,等.中国结直肠癌健康风险评估模型研究.中国慢性病预防与控制, 2018, 26(5):325-328.
6Iannone A, Losurdo G, Pricci M, et al. Stool Investigations for colorectal cancer screening:from occult blood test to DNA analysis. J Gastrointest Cancer, 2016, 47(2):143-151.
7Robertson DJ, Lee JK, Boland CR, et al. Recommendations on fecal immunochemical testing to screen for colorectal neoplasia:a consensus statement by the US multi-society task force on colorectal cancer. Gastroenterology, 2017, 152(5):1217-1237.e3.
8Hashimoto Y, Zumwalt TJ, Goel A. DNA methylation patterns as noninvasive biomarkers and targets of epigenetic therapies in colorectal cancer. Epigenomics, 2016, 8(5):685-703.
9US Preventive Services Task Force; Bibbins-Domingo K, Grossman DC, et al. Screening for colorectal cancer:US preventive services task force recommendation statement. JAMA, 2016, 315(23):2564-2575.
10蒋曦依,李璐,唐慧娟,等.结直肠癌高危人群多因素风险预测模型及评价.浙江大学学报:医学版, 2018, 47(2):194-200.
11Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics,2017. CA Cancer J Clin, 2017, 67(3):104-117.
12张玥,石菊芳,黄慧瑶,等.中国人群结直肠癌疾病负担分析.中华流行病学杂志, 2015, 36(7):709-714.
13Pil L, Fobelets M, Putman K, et al. Cost-effectiveness and budget impact analysis of a population-based screening program for colorectal cancer. Eur J Intern Med, 2016, 32:72-78.
14Wells BJ, Kattan MW, Cooper GS, et al. Colorectal cancer predicted risk online(CRC-PRO)calculator using data from the multi-ethnic cohort study. J Am Board Fam Med, 2014, 27(1):42-55.
15Jung YS, Park CH, Kim NH, et al. Identifying the optimal strategy for screening of advanced colorectal neoplasia. J Gastroenterol Hepatol, 2017, 32(5):1003-1010.
16Honein-AbouHaidar GN, Kastner M, Vuong V, et al. Systematic review and meta-study synthesis of qualitative studies evaluating facilitators and barriers to participation in colorectal cancer screening. Cancer Epidemiol Biomarkers Prev, 2016, 25(6):907-917.
17张海燕,谭婧宇,梁玲,等.重庆地区结直肠癌高危人群结直肠镜免费筛查的依从性及影响因素研究.重庆医科大学学报,2016, 41(12):1263-1267.
18袁平,顾晋. 2006~2015年中国大肠癌筛查人群依从性的Meta分析.中国肿瘤, 2017, 26(4):241-248.
19Provenzale D, Gupta S, Ahnen DJ, et al. NCCN Guidelines insights:colorectal cancer screening, version 1.2018. J Natl Compr Canc Netw, 2018, 16(8):939-949.
20Win AK, Macinnis RJ, Hopper JL, et al. Risk prediction models for colorectal cancer:a review. Cancer Epidemiol Biomarkers Prev,2012, 21(3):398-410.
21陆绍龙,徐艳松,李辉,等. 2014-2016年广西南宁市西乡塘区结直肠癌筛查成本效益分析.结直肠肛门外科, 2017, 23(6):698-701.
22Colditz GA, Atwood KA, Emmons K, et al. Harvard report on cancer prevention volume 4:Harvard Cancer Risk Index. Risk Index Working Group, Harvard Center for Cancer Prevention.Cancer Causes Control, 2000, 11(6):477-488.
23Yeoh KG, Ho KY, Chiu HM, et al. The Asia-Pacific Colorectal Screening score:a validated tool that stratifies risk for colorectal advanced neoplasia in asymptomatic Asian subjects. Gut, 2011,60(9):1236-1241.
24Chen S, Wang W, Lee S, et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA, 2006, 296(12):1479-1487.
25Imperiale TF, Wagner DR, Lin CY, et al. Using risk for advanced proximal colonic neoplasia to tailor endoscopic screening for colorectal cancer. Ann Intern Med, 2003, 139(12):959-965.
26Emmons KM, Wong M, Puleo E, et al. Tailored computer-based cancer risk communication:correcting colorectal cancer risk perception. J Health Commun, 2004, 9(2):127-141.
27Park Y, Freedman AN, Gail MH, et al. Validation of a colorectal cancer risk prediction model among white patients age 50 years and older. J Clin Oncol, 2009, 27(5):694-698.
28Freedman AN, Seminara D, Gail MH, et al. Cancer risk prediction models:a workshop on development, evaluation, and application. J Natl Cancer Inst, 2005, 97(10):715-723.
29Kolonel LN, Henderson BE, Hankin JH, et al. A multiethnic cohort in Hawaii and Los Angeles:baseline characteristics. Am J Epidemiol, 2000, 151(4):346-357.
30Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression:a bad idea. Stat Med, 2006, 25(1):127-141.
31Kattan MW, Zelefsky MJ, Kupelian PA, et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol, 2000,18(19):3352-3359.
32Ness RM, Holmes AM, Klein R, et al. Cost-utility of one-time colonoscopic screening for colorectal cancer at various ages. Am J Gastroenterol, 2000, 95(7):1800-1811.
33汪晓东,曹霖,陈珊珊,等. ACPGBI结直肠癌评分系统在临床中的应用现状.中国医师杂志, 2008, 10(9):1293-1295.
34Wong MC, Lam TY, Tsoi KK, et al. A validated tool to predict colorectal neoplasia and inform screening choice for asymptomatic subjects. Gut, 2014, 63(7):1130-1136.
35Chen G, Mao B, Pan Q, et al. Prediction rule for estimating advanced colorectal neoplasm risk in average-risk populations in southern Jiangsu Province. Chin J Cancer Res, 2014, 26(1):4-11.
2Navarro M, Nicolas A, Ferrandez A, et al. Colorectal cancer population screening programs worldwide in 2016:an update.World J Gastroenterol, 2017, 23(20):3632-3642.
3Day LW, Velayos F. Colorectal cancer screening and surveillance in the elderly:updates and controversies. Gut Liver, 2015, 9(2):143-151.
4Freedman AN, Slattery ML, Ballard-Barbash R, et al. Colorectal cancer risk prediction tool for white men and women without known susceptibility. J Clin Oncol, 2009, 27(5):686-693.
5丁兰君,赵丽中,王媛,等.中国结直肠癌健康风险评估模型研究.中国慢性病预防与控制, 2018, 26(5):325-328.
6Iannone A, Losurdo G, Pricci M, et al. Stool Investigations for colorectal cancer screening:from occult blood test to DNA analysis. J Gastrointest Cancer, 2016, 47(2):143-151.
7Robertson DJ, Lee JK, Boland CR, et al. Recommendations on fecal immunochemical testing to screen for colorectal neoplasia:a consensus statement by the US multi-society task force on colorectal cancer. Gastroenterology, 2017, 152(5):1217-1237.e3.
8Hashimoto Y, Zumwalt TJ, Goel A. DNA methylation patterns as noninvasive biomarkers and targets of epigenetic therapies in colorectal cancer. Epigenomics, 2016, 8(5):685-703.
9US Preventive Services Task Force; Bibbins-Domingo K, Grossman DC, et al. Screening for colorectal cancer:US preventive services task force recommendation statement. JAMA, 2016, 315(23):2564-2575.
10蒋曦依,李璐,唐慧娟,等.结直肠癌高危人群多因素风险预测模型及评价.浙江大学学报:医学版, 2018, 47(2):194-200.
11Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics,2017. CA Cancer J Clin, 2017, 67(3):104-117.
12张玥,石菊芳,黄慧瑶,等.中国人群结直肠癌疾病负担分析.中华流行病学杂志, 2015, 36(7):709-714.
13Pil L, Fobelets M, Putman K, et al. Cost-effectiveness and budget impact analysis of a population-based screening program for colorectal cancer. Eur J Intern Med, 2016, 32:72-78.
14Wells BJ, Kattan MW, Cooper GS, et al. Colorectal cancer predicted risk online(CRC-PRO)calculator using data from the multi-ethnic cohort study. J Am Board Fam Med, 2014, 27(1):42-55.
15Jung YS, Park CH, Kim NH, et al. Identifying the optimal strategy for screening of advanced colorectal neoplasia. J Gastroenterol Hepatol, 2017, 32(5):1003-1010.
16Honein-AbouHaidar GN, Kastner M, Vuong V, et al. Systematic review and meta-study synthesis of qualitative studies evaluating facilitators and barriers to participation in colorectal cancer screening. Cancer Epidemiol Biomarkers Prev, 2016, 25(6):907-917.
17张海燕,谭婧宇,梁玲,等.重庆地区结直肠癌高危人群结直肠镜免费筛查的依从性及影响因素研究.重庆医科大学学报,2016, 41(12):1263-1267.
18袁平,顾晋. 2006~2015年中国大肠癌筛查人群依从性的Meta分析.中国肿瘤, 2017, 26(4):241-248.
19Provenzale D, Gupta S, Ahnen DJ, et al. NCCN Guidelines insights:colorectal cancer screening, version 1.2018. J Natl Compr Canc Netw, 2018, 16(8):939-949.
20Win AK, Macinnis RJ, Hopper JL, et al. Risk prediction models for colorectal cancer:a review. Cancer Epidemiol Biomarkers Prev,2012, 21(3):398-410.
21陆绍龙,徐艳松,李辉,等. 2014-2016年广西南宁市西乡塘区结直肠癌筛查成本效益分析.结直肠肛门外科, 2017, 23(6):698-701.
22Colditz GA, Atwood KA, Emmons K, et al. Harvard report on cancer prevention volume 4:Harvard Cancer Risk Index. Risk Index Working Group, Harvard Center for Cancer Prevention.Cancer Causes Control, 2000, 11(6):477-488.
23Yeoh KG, Ho KY, Chiu HM, et al. The Asia-Pacific Colorectal Screening score:a validated tool that stratifies risk for colorectal advanced neoplasia in asymptomatic Asian subjects. Gut, 2011,60(9):1236-1241.
24Chen S, Wang W, Lee S, et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA, 2006, 296(12):1479-1487.
25Imperiale TF, Wagner DR, Lin CY, et al. Using risk for advanced proximal colonic neoplasia to tailor endoscopic screening for colorectal cancer. Ann Intern Med, 2003, 139(12):959-965.
26Emmons KM, Wong M, Puleo E, et al. Tailored computer-based cancer risk communication:correcting colorectal cancer risk perception. J Health Commun, 2004, 9(2):127-141.
27Park Y, Freedman AN, Gail MH, et al. Validation of a colorectal cancer risk prediction model among white patients age 50 years and older. J Clin Oncol, 2009, 27(5):694-698.
28Freedman AN, Seminara D, Gail MH, et al. Cancer risk prediction models:a workshop on development, evaluation, and application. J Natl Cancer Inst, 2005, 97(10):715-723.
29Kolonel LN, Henderson BE, Hankin JH, et al. A multiethnic cohort in Hawaii and Los Angeles:baseline characteristics. Am J Epidemiol, 2000, 151(4):346-357.
30Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression:a bad idea. Stat Med, 2006, 25(1):127-141.
31Kattan MW, Zelefsky MJ, Kupelian PA, et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol, 2000,18(19):3352-3359.
32Ness RM, Holmes AM, Klein R, et al. Cost-utility of one-time colonoscopic screening for colorectal cancer at various ages. Am J Gastroenterol, 2000, 95(7):1800-1811.
33汪晓东,曹霖,陈珊珊,等. ACPGBI结直肠癌评分系统在临床中的应用现状.中国医师杂志, 2008, 10(9):1293-1295.
34Wong MC, Lam TY, Tsoi KK, et al. A validated tool to predict colorectal neoplasia and inform screening choice for asymptomatic subjects. Gut, 2014, 63(7):1130-1136.
35Chen G, Mao B, Pan Q, et al. Prediction rule for estimating advanced colorectal neoplasm risk in average-risk populations in southern Jiangsu Province. Chin J Cancer Res, 2014, 26(1):4-11.